Neurocrine Biosciences is nearing a $2.5+ billion acquisition of Soleno Therapeutics, the biotech behind Vykat, the first drug approved for hyperphagia in Prader-Willi syndrome. The deal, expected to close by Monday, would value Soleno at a $50+ per share premium over its $2bn market cap, driven by Vykat’s $190 million 2023 revenue and projected $2.3 billion annual peak sales. This marks Neurocrine’s first major acquisition, expanding its obesity and rare disease pipeline beyond its existing Ingrezza treatment for tardive dyskinesia.

The move reflects intensifying competition among midsized drugmakers to acquire niche biotechs, with $63.3 billion in U.S. biotech M&A deals closed Q1 2024—the fifth-best quarter in a decade. BioMarin ($10.3bn market cap) and Genmab ($8bn deal for Merus) exemplify this trend. Soleno’s Vykat, launched March 2023, has enrolled 1,250 patients by year-end 2025, underscoring demand for rare disease therapies. Neurocrine’s pipeline also targets schizophrenia and epilepsy, positioning it as a diversified biopharma player.

The acquisition aligns with broader sector consolidation, as giants like Eli Lilly ($7.8bn Centessa deal) and Biogen ($5.6bn Apellis deal) dominate headlines. However, Neurocrine’s focus on smaller, specialized assets highlights a strategic shift toward high-growth, niche markets. Analysts note this could reshape Neurocrine’s revenue mix, with Soleno’s obesity treatment potentially becoming a blockbuster amid rising demand for Prader-Willi therapies.

Why this matters: Rare disease biotech deals are surging as pharmaceutical firms prioritize specialized drugs with fewer competitors. Neurocrine’s bid for Soleno signals confidence in Vykat’s scalability and the growing value of precision medicine. With regulatory approvals accelerating, such acquisitions may redefine mid-sized drugmakers’ roles in the $500bn+ global biotech market.